factor for response to donor lymphocyte infusions in multiple myeloma The occurrence of graft-versus-host disease is the major predictive

[1]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[2]  Catherine J. Wu,et al.  Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. , 2004, Blood.

[3]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[4]  P. Sonneveld,et al.  Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Gienke R Boersma-Vreugdenhil,et al.  Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH. , 2003, Blood.

[7]  B. van Kessel,et al.  Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma , 2003, Clinical and experimental immunology.

[8]  M. V. van Oers,et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Barlogie,et al.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.

[10]  H. Kittler,et al.  Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Collins,et al.  Donor leukocyte infusions for multiple myeloma , 2000, Bone Marrow Transplantation.

[12]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[13]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[14]  G. Hill,et al.  Cytokine cascades in acute graft-versus-host disease. , 1997, Transplantation.

[15]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[16]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.